Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAX Corporation (NYSE: IMAX) files reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detail on its entertainment technology business, capital structure, and material events. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe the company’s convertible notes, credit facilities, and operating results.
Among its recent filings, IMAX has reported the entry into a Seventh Amended and Restated Credit Agreement, which increased its revolving borrowing capacity and set out leverage covenants, guarantees, and use of proceeds. The company has also filed an 8-K describing the issuance of 0.75% convertible senior notes due 2030, outlining interest terms, maturity, conversion rights, redemption conditions, and related capped call transactions intended to reduce potential dilution or offset certain cash payments upon conversion.
Investors reviewing IMAX filings can use this page to access documents that discuss the company’s financial obligations, including convertible debt, revolving credit facilities, and related covenants. Filings also reference IMAX’s global footprint, with systems operating in multiple countries and territories, and its listing on the New York Stock Exchange under the symbol IMAX.
Stock Titan’s SEC filings page for IMAX provides real-time access to new submissions from the EDGAR system, along with AI-powered summaries designed to explain the key terms and implications of complex filings. Users can quickly identify items related to financing transactions, results of operations, and other material corporate developments, and can locate information relevant to topics such as note conversion features, redemption provisions, and reporting covenants.
IMAX Corporation’s Chief Financial Officer and EVP, Natasha Fernandes, reported an options exercise and share sale involving the company’s common shares. On 11/24/2025, she exercised 2,652 stock options with an exercise price of $22.49 per share, converting them into 2,652 common shares. That same day, she sold 2,652 common shares at an average price of $36.1479 per share, returning her directly held common share balance to 31,257 shares.
The options were originally granted in 2019 and are scheduled to expire on March 7, 2026, having vested in four annual installments between 2020 and 2023. Following these transactions, Ms. Fernandes’ aggregate remaining outstanding restricted share unit balance is 39,734, and her common share balance remains 31,257, reflecting a same-day exercise-and-sale transaction structure.
IMAX Corp: Orbis Investment Management Limited and Allan Gray Australia Pty Ltd filed Amendment No. 4 to Schedule 13G, reporting beneficial ownership in IMAX common stock. They report 5,241,883 shares, representing 9.7% of the class, with the event dated September 30, 2025.
Orbis has sole voting and dispositive power over 5,222,063 shares, and Allan Gray Australia has sole voting and dispositive power over 19,820 shares. The filers certify the holdings were acquired and are held in the ordinary course of business and not to change or influence control. They are classified as non‑U.S. institutions equivalent to investment advisers.
IMAX: Macquarie entities filed Amendment No. 2 to Schedule 13G reporting beneficial ownership of 4,612,983 common shares, representing 8.58% of the class as of 09/30/2025.
Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report sole voting and sole dispositive power over 4,612,983 shares. Macquarie Group Limited reports an aggregate beneficial amount of 4,612,983 shares with zero sole or shared voting/dispositive power on its cover page.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
IMAX Corp reported a Form 4 for CEO and Director Richard L. Gelfond, who gifted 40,000 common shares on 11/10/2025 (transaction code G) to a donor‑advised fund for charitable purposes. After the transfer, he beneficially owns 564,599 common shares directly.
The filing also lists his outstanding awards following the transaction: 1,818,695 options and 294,433 restricted share units. It states the timing relates to changes in tax regulations taking effect on 01/01/2026.
IMAX (IMAX) executive Mark Welton reported an option exercise and share sale. On 11/10/2025, he exercised stock options into 49,504 common shares at $22.49 per share and sold 49,504 common shares at a price of $35.228.
Following these transactions, he beneficially owns 153,323 common shares directly. The filing notes 70,609 restricted share units outstanding after these transactions and that the options exercised were issued in 2019 and set to expire on March 7, 2026.
IMAX Chief Commercial Officer Giovanni M. Dolci reported an option exercise and same‑day sale. On 11/10/2025, he exercised 6,188 stock options at $22.49 and sold 6,188 common shares at a weighted average price of $34.2452, leaving 33,000 common shares held directly.
The options were issued in 2019 and are set to expire on March 7, 2026. The filing notes remaining restricted share units of 21,574 following these transactions.
IMAX (IMAX) reported an insider transaction by CTO & EVP Pablo Calamera. On 11/10/2025, he executed a sale coded “S” of 20,586 common shares at a price of $34.2255 per share. Following the sale, his beneficially owned common shares total 40,886, held directly.
The filing also notes remaining restricted share units of 32,863 after the reported transactions. This Form 4 reflects a routine insider share sale and updated holdings.
IMAX filed a Form 144 indicating a proposed sale of 20,586 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $704,566.14 and an approximate sale date of 11/10/2025.
The shares to be sold were acquired via restricted stock vesting under a registered plan: 17,586 on 03/07/2024 and 3,000 on 03/07/2023, each for services rendered. Shares outstanding were 53,798,934; this is a baseline figure, not the amount being offered.
IMAX reported a Form 144 notice for a proposed sale of 49,504 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $1,743,926.91 and an approximate sale date of 11/10/2025 on the NYSE. The shares were acquired on 11/10/2025 via the exercise of options under a registered plan, with payment in cash. As context, 53,798,934 shares were outstanding.
IMAX filed a Form 144 notice for a planned sale of 6,188 common shares. The filing lists Morgan Stanley Smith Barney as broker, an aggregate market value of $211,909.30, and an approximate sale date of 11/10/2025 on the NYSE.
The shares were acquired on 11/10/2025 through the exercise of options under a registered plan, with payment in cash. Shares outstanding were 53,798,934. The signer represents they do not know of undisclosed material adverse information about the company.